KD Pharma, a pharmaceutical and nutraceutical products developer, agreed to acquire manufacturing assets of Rohner, a Switzerland based custom manufacturer of active pharmaceutical ingredients. Financial terms were not disclosed. “Rohner was known for its unique chemical processes and technological capabilities, enabling it to manufacture difficult, multi-step pharmaceutical intermediates and APIs. This is a natural fit with our strategy to create health solutions and provide value to customers by utilizing a unique toolbox of technologies,” Oscar Groet, KD Pharma Group CEO.